Who are Product 2 - AquaCelle Fish Oil Ethyl Ester's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/product-2-aquacelle-fish-oil-ethyl-ester.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Product 2 - AquaCelle Fish Oil Ethyl Ester — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Product 2 - AquaCelle Fish Oil Ethyl Ester (Product 2 - AquaCelle Fish Oil Ethyl Ester) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Omega-3 fatty acid supplement / Triglyceride-lowering agent. Area: Cardiovascular.

marketed Omega-3 fatty acid supplement / Triglyceride-lowering agent Multiple targets including PPAR-alpha, GPR120, and hepatic lipid metabolism pathways Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Product 2 - AquaCelle Fish Oil Ethyl Ester (Product 2 - AquaCelle Fish Oil Ethyl Ester) — RDC Clinical Pty Ltd. AquaCelle Fish Oil Ethyl Ester provides omega-3 polyunsaturated fatty acids (EPA and DHA) that reduce triglycerides and support cardiovascular health.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Product 2 - AquaCelle Fish Oil Ethyl Ester TARGET	Product 2 - AquaCelle Fish Oil Ethyl Ester	RDC Clinical Pty Ltd	marketed	Omega-3 fatty acid supplement / Triglyceride-lowering agent	Multiple targets including PPAR-alpha, GPR120, and hepatic lipid metabolism pathways

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Omega-3 fatty acid supplement / Triglyceride-lowering agent class)

RDC Clinical Pty Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Product 2 - AquaCelle Fish Oil Ethyl Ester — Competitive Intelligence Brief. https://druglandscape.com/ci/product-2-aquacelle-fish-oil-ethyl-ester. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab